In less than a year, Graphite Bio has sped from series A to Wall Street welcome as it rustles up capital to fund gene-editing treatments for sickle cell disease, an immune system disorder and ...

OneD Battery Sciences (“OneD”), the leader in silicon anode technologies for EV batteries, and Koch Modular Process Systems, LLC (Koch Modular), a glo ...

Since much of the research is already well underway at Stanford, Graphite Bio aims to start treating sickle cell patients in 2021, with multiple programs close behind in the near future.

Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication.

Vancouver, March 02, 2023 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp (“Ceylon Graphite”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that it has completed the world’s first ...

GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease. Initial proof-of-concept data from Phase 1/2 CEDAR ...

Lithium iron phosphate (LFP) battery cells are ubiquitous in electric vehicles and stationary energy storage because they are cheap and have a long lifetime. This webinar will show our studies ...

Gene-editing company Graphite Bio’s $238 million IPO was the biggest in biotech this week as it works toward human tests of a therapy that corrects the genetic mutation behind sickle cell disease.

Graphite Bio (NASDAQ: GRPH) announced the initiation of patient dosing in the Phase 1/2 CEDAR trial with its asset GPH101 (nulabeglogene autogedtemcel) in people with sickle cell disease (SCD).

Three weeks ago, on January 5, Graphite Bio announced a voluntary pause of their Phase I/II CEDAR clinical trial of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) after ...